Market access is the work between a marketing authorisation and a paid prescription — and in Germany that gap is wide. AMNOG sets your price on recognised added benefit, not your ambition; distribution and compliance run on their own rules. This is the map of German pharma market access, and how the pieces fit together.
A marketing authorisation lets you sell a medicine in Germany. Market access decides whether, to whom and at what price the statutory system actually pays for it — and roughly 90% of Germans are covered by statutory insurance, so that decision is the market.
For a foreign company, this is the part the FDA-shaped mental model misses. In Germany, approval and price are separate events run by separate bodies: the EMA or national authority approves; the G-BA, IQWiG and the statutory insurers decide value and price through AMNOG. Everything downstream — distribution, pharmacovigilance, hospital and pharmacy access — sits on top of that. Get access right and the authorisation pays off; get it wrong and an approved drug earns little.
Authorisation is permission. Market access is revenue. They are not the same project.
Five stages turn an approved medicine into German revenue. The discipline is preparing the value story before launch, not after.
An EU centralised or national authorisation — permission to place the product on the market. See the four authorisation routes.
Since the 2023 GKV-FinStG reform you set your own price only for the first six months before the negotiated price applies.
The G-BA commissions IQWiG to rate added benefit against a comparator. That rating sets the ceiling on your price. See AMNOG explained.
A negotiated reimbursement price (with arbitration if needed) applies from month seven, with a clawback on the free-price period.
Supply through wholesalers and pharmacies under GDP and serialisation, with pharmacovigilance running continuously. See pharma distribution.
Access is not one task. These are the workstreams that decide it — each with a deeper guide.
The G-BA / IQWiG benefit assessment and the price negotiation that follows — the single biggest determinant of your German revenue.
AMNOG explained →The authorisation path — centralised, decentralised, mutual-recognition or national — and how it feeds the access timeline.
Authorisation routes →The regulated channel to ~18,000 pharmacies through wholesalers under GDP and securPharm serialisation.
Pharma distribution →Pharmacovigilance, GMP/GDP and the officers the law requires — the duties that run for as long as you sell.
PV & GxP →Getting onto hospital formularies and reaching specialists — a separate channel with its own gatekeepers.
Hospital access →The idea under all of it: approval makes you eligible; reimbursement, price and channel decide revenue.
Read the thesis →Foreign pharma bringing a first product into Germany and discovering that approval was the easy half.
Companies 12–24 months from launch who need the AMNOG comparator and evidence strategy set now, not later.
Orphan, specialty and high-value products where the added-benefit case and hospital access make or break the price.
Selling devices as well as medicines? See medtech market access in Germany. Entering from a specific country? See the tailored guides for US and Swiss companies, or start with the market-entry strategy overview.
We own the access and commercial layer and coordinate the regulatory and PV specialists — so the value story is ready when AMNOG starts.
Comparator, evidence and pricing strategy for AMNOG — built before launch, when it still changes the outcome.
Local representation, the required officers and the distribution channel, stood up and kept compliant. See local representation.
Price negotiation support, hospital and pharmacy access, and the payer relationships that turn approval into revenue.
It is everything between a marketing authorisation and a reimbursed prescription: the AMNOG benefit assessment and price negotiation, listing, distribution through wholesalers and pharmacies, and the compliance operations that keep the product on the market. Because ~90% of Germans have statutory insurance, market access — not approval — determines revenue.
After launch, the G-BA commissions IQWiG to assess the medicine's added benefit against an appropriate comparator. That rating sets the ceiling for a negotiated reimbursement price, which since the 2023 reform applies from the seventh month. A weak or unproven added benefit can collapse the price regardless of sales.
Before launch. The comparator choice and the clinical or health-economic evidence that win a good added-benefit rating must be planned during development, not assembled after approval. Starting late is the most common and most expensive mistake.
No. An EU centralised authorisation lets you place the product on the market across the EU, but pricing and reimbursement are national. In Germany that means AMNOG, the G-BA and the statutory insurers — a separate process from the authorisation.
Builds and runs the access strategy: the AMNOG comparator and evidence plan, the pricing and negotiation approach, the required local representation and compliance roles, and hospital, pharmacy and payer access — the work that turns an approved medicine into a paid one.
Start with a focused session — we'll map the AMNOG comparator, the evidence and the access path for your specific product.